Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Overview

The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2018

Detailed Description

This will be an open label clinical trial. We plan to treat 10 adults with AA (with at least 2 patches of alopecia involving the scalp), AT or AU with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth. Laboratory evaluation will be performed before and during treatment in order to monitor for adverse effects of the medication.

Interventions

  • Drug: Tofacitinib ointment
    • Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.

Arms, Groups and Cohorts

  • Experimental: Tofacitinib ointment
    • Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.

Clinical Trial Outcome Measures

Primary Measures

  • Percent Change in Severity of Alopecia Tool (SALT) Score
    • Time Frame: 6 Months
    • SALT score range is from 0 (no hair loss) to 100 (100% hair loss). A positive percent change from baseline corresponds to a reduction in SALT score, and in this study study will be measured between baseline and 6 months.

Secondary Measures

  • Treatment Response Assessed as the Number of Participants With Hair Regrowth
    • Time Frame: 6 Months
    • Clinical photographs will be used to demonstrate presence or absence of hair regrowth. Presented is a count of people that did respond to treatment.

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of AA with at least 2 patches of alopecia involving the scalp, AT or AU – Stable hair loss present for 6 months or longer – No treatment for alopecia areata in the past 1 month – No evidence of spontaneous hair regrowth Exclusion Criteria:

  • Patients have received treatment known to affect alopecia areata within 1 month of enrolling in the study – Patients whose current episode of AT or AU is more than 5 years – Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin) – Patients known to be HIV or hepatitis B or C positive – Patients with positive tuberculin skin test or positive QuantiFERON® TB test – Patients with leukopenia or anemia – Patients with renal or hepatic impairment – Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNF-α inhibitors – Women who are pregnant or nursing

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Yale University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Brett King, MD, PhD, Principal Investigator, Yale University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.